Objective: To investigate the change and relationship between serum high-mobility group box-1(HMGB1) and related inflammatory cytokines level in patients suffer with bone metastatic pain. Methods: Collection of the bone cancer pain patients who received analgesic therapy the department of pain in The First Affiliated Hospital of Jiaxing University from November 2016 to August 2016. Serum concentration of HMGB1, the Receptor of Advanced Glycation Endproducts (RAGE), monocyte chemotactic protein-1(MCP-1), tumor necrosis factor -α (TNF-α), interleukin-1β (IL-1β), interleukin-10 (IL-10), interleukin-13 (IL-13), and transforming growth factor-β (TGF-β) levels were determined in 15 healthy individuals as healthy donor and 15 patients with bone metastatic pain by enzyme-linked immunosorbent (ELISA) . The healthy individuals and patients with bone metastatic pain were collected before treatment and on 7 d after the treatment. Results: The serum concentration of HMGB1 and RAGE were significantly increased in tumorous group compared with healthy group[(8.8±2.3) vs (1.9±1.1) μg/L,(231±16) vs (46±20) ng/L); t=7.10,12.44, both P<0.05], then decreased after analgesic therapy [(4.77±1.36) μg/L, (129.80±29.32) ng/L, t=7.10, 12.44, both P<0.05]. The serum concentration of proinflammatory cytokines such as MCP-1, TNF-α, and IL-1β were significantly increased in tumorous group when compared with healthy group, and decreased after analgesic therapy (all P<0.05). The expression of anti-inflammatory cytokines such as IL-10, IL-13, and TGF-β were significantly increased in tumorous group when compared with healthy group, and decreased after analgesic therapy (all P<0.05).Compared with healthy group, the levels of MCP-1/IL-10, MCP-1/IL-13, MCP-1/TGF-β, TNF-α/IL-10, TNF-α/IL-13, TNF-α/TGF-β, IL-1β/IL-10, IL-1β/IL-13, IL-1β/TGF-β were significantly increased in tumorous group (all P<0.05). Conclusion: HMGB1 may adjust the proinflammatory-anti-inflammatory system homeostasis to participate in the development of bone metastatic pain.
目的： 检测骨癌痛患者血清中高迁移率族蛋白1（HMGB1）及相关炎症因子指标，探讨骨癌痛患者高迁移率族蛋白1与炎症介质之间的相互关系。 方法： 收集嘉兴学院附属第一医院2016年11月至2017年8月疼痛科收住的晚期骨癌痛接受镇痛治疗的患者15例作为骨癌痛组，选择同期健康体检者15例作为健康对照组。酶联免疫吸附试验（ELISA）法检测骨癌痛组治疗前、治疗后1周以及对照组血清中HMGB1、晚期糖基化终末产物受体（RAGE）、单核细胞趋化蛋白-1（MCP-1）、肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）、白细胞介素-10（IL-10）、白细胞介素-13（IL-13）和转化生长因子-β（TGF-β）的表达。 结果： 健康对照组血清HMGB1、RAGE表达水平分别为（1.9±1.1）μg/L、（46±20）ng/L，骨癌痛患者治疗前血清HMGB1、RAGE表达水平分别为（8.8±2.3）μg/L、（231±16）ng/L，明显高于健康对照组（t=10.490、27.79，均P<0.05），经镇痛治疗后其表达水平分别为（4.77±1.36）μg/L、（129.80±29.32）ng/L，均低于治疗前，差异均有统计学意义（t=7.10、12.44，均P<0.05）。骨癌痛患者治疗前血清促炎因子MCP-1、TNF-α和IL-1β水平均高于健康对照组，且在治疗后均有下降（均P<0.05）。骨癌痛患者抗炎因子IL-10、IL-13、TGF-β水平均高于健康对照组，且在治疗后均有下降（均P<0.05）。骨癌痛患者促炎因子/抗炎因子比值MCP-1/IL-10、MCP-1/IL-13、MCP-1/TGF-β、TNF-α/IL-10、TNF-α/IL-13、TNF-α/TGF-β、IL-1β/IL-10、IL-1β/IL-13、IL-1β/TGF-β与健康对照组相比均有增高，差异均有统计学意义（均P<0. 05）。 结论： HMGB1可能通过调节促炎-抗炎系统稳态参与骨癌痛的发生发展过程。.
Keywords: Bone neoplasms; High mobility group proteins; Pain.